Evidence map›Paper›PMID 36686635›Full record

ArticleOpen forum infectious diseases2023

Statistical Analysis of Mortality Rates of Coronavirus Disease 2019 (COVID-19) Patients in Japan Across the 4C Mortality Score Risk Groups, Age Groups, and Epidemiological Waves: A Report From the Nationwide COVID-19 Cohort.

Hiroaki Baba, Saori Ikumi, Shotaro Aoyama, Tetsuo Ishikawa, Yusuke Asai, Nobuaki Matsunaga, Norio Ohmagari, Hajime Kanamori, Koichi Tokuda, Takuya Ueda and 1 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Observational
  2. Article
  3. Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave - a nationwide study in Japan.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hiroaki BabaDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0001-5487-6698
Saori IkumiDepartment of Anesthesiology and Perioperative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shotaro AoyamaAdvanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, Yokohama, Japan.
Tetsuo IshikawaAdvanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, Yokohama, Japan.
Yusuke AsaiAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Nobuaki MatsunagaAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4622-8970
Hajime KanamoriDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Koichi TokudaDepartment of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Takuya UedaDepartment of Clinical Imaging, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0002-0913-5791
Eiryo KawakamiAdvanced Data Science Project, RIKEN Information R&D and Strategy Headquarters, Yokohama, Japan.
Tohoku University · JPNational Center for Global Health and Medicine · JPChiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The mortality rates of coronavirus disease 2019 (COVID-19) have been changed across the epidemiological waves. The aim was to investigate the differences in mortality rates of COVID-19 patients in Japan across the 6 epidemiological waves stratified by age group and Coronavirus Clinical Characterisation Consortium (4C) mortality score risk group. Methods: A total of 56 986 COVID-19 patients in the COVID-19 Registry Japan from 2 March 2020 to 1 February 2022 were enrolled. These patients were categorized into 4 risk groups based on their 4C mortality score. Mortality rates of each risk group were calculated separately for different age groups: 18-64, 65-74, 75-89, and ≥90 years. In addition, mortality rates across the wave periods were calculated separately in 2 age groups: <75 and ≥75 years. All calculated mortality rates were compared with reported data from the United Kingdom (UK) during the early epidemic. Results: The mortality rates of patients in Japan were significantly lower than in the UK across the board, with the exception of patients aged ≥90 years at very high risk. The mortality rates of patients aged ≥75 years at very high risk in the fourth and fifth wave periods showed no significant differences from those in the UK, whereas those in the sixth wave period were significantly lower in all age groups and in all risk groups. Conclusions: The present analysis showed that COVID-19 patients had a lower mortality rate in the most recent sixth wave period, even among patients ≥75 years old at very high risk.

Indexed as

4C mortality scoreCOVID-19elderlyepidemic waveJapan

Identifiers

PMID36686635
PMCPMC9846187
OpenAlexW4309932354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.